References
- O'Doherty M J, Hoskin P J. Positron emission tomography in the management of lymphomas: a summary. Eur J Nucl Med Mol Imag 2003; 30(s1)s128–s130
- Hoskin P J. PET in lymphoma: what are the oncologist's need. Eur J Nucl Med Mol Imag 2003; 30(s1)s37–s41
- Delbeke D, Martin W H, Morgan D S, Kinney M C, Feurer I, Kovalsky E, et al. 2-deoxy-2-[F-18-fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imag Biol 2002; 4: 104–114
- Kostakoglu L, Coleman M, Leonard J P, Kuji I, Zoe H, Goldsmith S J. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018–1027
- Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356–1363
- Guay C, Lepine M, Verrault J, Bernard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225–1231
- Weihrauch M R, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930–2934
- Lavely W C, Delbeke D, Greer J P, Morgan D S, Byrne D W, Price R R, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 307–315
- Romer W, Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imag 1998; 1: 101–110
- Spaepen K, Stroobants S, Dupont P, Thomas J, Vandeberghe P, Balzarini J, et al. Can positron emission tomography with [18F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity. Br J Haematol 2001; 115: 272–278
- Fishbach W. Primary gastric lymphoma of MALT: considerations of pathogenesis, diagnosis and therapy. Can J Gastroenterol 2000; 14(Suppl D)44D–50D
- Kostakoglu L, Goldsmith S J. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears. Eur J Nucl Med 2000; 27: 1564–1578
- Reske S N. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imag 2003; s1: S89–S96
- Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio J A, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875–3876
- Barrington S F, O'Doherty M J. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imag 2003; 30(s1)s117–s127
- Hoffmann M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10: 1185–1189
- Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64: 336–340
- Beal K P, Yeung H W, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphoma of the MALT type: a report of 42 cases. Ann Oncol 2005; 16: 473–480
- Cavalli F, Isaacson P G, Gascoyne R D, Zucca E. MALT lymphomas. Hematology (Am Soc Hematol Educ Program) 2001; 241–258
- Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz M K, et al. International extranodal lymphoma study group. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489–2495
- Thieblemont C, de la Fouchardiere A, Coiffier B. Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma 2003; 3: 212–224